Linking Insights for Multiple Myeloma Patient Care
Unite for MM: Linking Insights for MM Patient Care
With the recent approvals of immunotherapies to treat relapsed/refractory multiple myeloma (RRMM), such as bispecific antibodies (BsAbs) and chimeric antigen receptor (CAR) T-cell therapies, patients and health care professionals (HCPs) now have more treatment options than ever before.1-3 However, this increasingly complex treatment landscape can be challenging to navigate with limited information on treatment decision-making perspectives of patients and HCPs.1
Together with Pfizer, a multinational Steering Committee composed of members from across the multiple myeloma (MM) community developed the first large-scale global survey of its kind to understand RRMM care.1
Key gaps and unmet needs for the adoption of recently approved immunotherapies that may impact patient care1
Explore the Unite for MM website to discover survey insights and what they may mean for you
References
- Ailawadhi S, Biru Y, Clavreul S, et al. Perspectives of healthcare providers and patients with relapsed/refractory multiple myeloma on treatment priorities and novel therapies. Patient Prefer Adherence. 2025;2025(19):1089-1104. Published April 2, 2025. Taylor & Francis Ltd. Reprinted by permission of the publisher Informa UK Limited trading as Taylor & Francis Ltd, http://www.tandfonline.com.
- Banerjee R, Biru Y, Cole CE, Faiman B, Midha S, Ailawadhi S. Disparities in relapsed or refractory multiple myeloma: recommendations from an interprofessional consensus panel. Blood Cancer J. 2024;14(1):149.
- Nishida H. Rapid progress in immunotherapies for multiple myeloma: an updated comprehensive review. Cancers (Basel). 2021;13(11):2712.